AR132701A2 - Neurotoxinas catiónicas - Google Patents
Neurotoxinas catiónicasInfo
- Publication number
- AR132701A2 AR132701A2 ARP240101240A ARP240101240A AR132701A2 AR 132701 A2 AR132701 A2 AR 132701A2 AR P240101240 A ARP240101240 A AR P240101240A AR P240101240 A ARP240101240 A AR P240101240A AR 132701 A2 AR132701 A2 AR 132701A2
- Authority
- AR
- Argentina
- Prior art keywords
- clostridial toxin
- dystonia
- engineered clostridial
- chain
- amino acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24068—Tentoxilysin (3.4.24.68), i.e. tetanus neurotoxin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
Abstract
La presente invención provee una toxina clostridial diseñada que comprende por lo menos una modificación de aminoácido, en donde dicha por lo menos una modificación de aminoácido incrementa el punto isoeléctrico (pI) de la toxina clostridial diseñada llevándolo a un valor que es por lo menos 0,2 unidades de pI superior al pI de una toxina clostridial por demás idéntica que carezca de dicha por lo menos una modificación de aminoácido. También se proveen usos correspondientes de la toxina clostridial diseñada en terapia. Reivindicación 1: Una toxina clostridial diseñada, caracterizada porque comprende por lo menos una modificación de aminoácido, en donde dicha por lo menos una modificación de aminoácido incrementa el punto isoeléctrico (pI) de la toxina clostridial diseñada llevándolo a un valor que es por lo menos 0,2 unidades de pI superior al pI de una toxina clostridial por demás idéntica que carezca de dicha por lo menos una modificación de aminoácido. Reivindicación 18: Un ácido nucleico caracterizada porque comprende una secuencia de ácidos nucleicos que codifica una toxina clostridial diseñada de acuerdo con cualquiera de las reivindicaciones 1 - 17. Reivindicación 19: Un método para producir una proteína toxina clostridial toxina diseñada de cadena simple que tiene una cadena liviana y una cadena pesada, caracterizado porque el método comprende expresar un ácido nucleico de acuerdo con la reivindicación 18 en un célula huésped adecuado, lisar la célula huésped de manera de proveer un material homogeneizado de célula huésped que contiene la proteína toxina clostridial toxina diseñada de cadena simple, y aislar la proteína toxina clostridial toxina diseñada de cadena simple. Reivindicación 20: Un método para activar una toxina clostridial diseñada, caracterizado porque el método comprende proveer una proteína toxina clostridial toxina diseñada de cadena simple obtenible mediante el método de acuerdo con la reivindicación 19, poner en contacto el polipéptido con una proteasa que escinde el polipéptido en un sitio de reconocimiento (sitio de escisión) situado entre la cadena liviana y cadena pesada, y convertir el polipéptido en un polipéptido dicadena en donde la cadena liviana y la cadena pesada se unen por intermedio de un enlace disulfuro. Reivindicación 21: Una toxina clostridial diseñada de acuerdo con cualquiera de las reivindicaciones 1 a 17, caracterizada porque es para su uso en medicina. Reivindicación 22: Una toxina clostridial diseñada de acuerdo con cualquiera de las reivindicaciones 1 a 17, caracterizada porque es para su uso en la prevención o tratamiento de una enfermedad o condición seleccionado entre: estrabismo, blefarospasmo, bizquera, distonía (por ejemplo distonía espasmódica, distonía oromandibular, distonía focal, distonía tardía, distonía de los miembros, distonía laríngea, distonía de los miembros, distonía cervical), tortícolis (por ejemplo tortícolis espasmódica), terapia de belleza (cosmética) aplicaciones que se beneficien de la incapacitación de células / músculos (vía regulación descendente o desactivación por SNARE), trastorno neuromuscular o condición de motilidad ocular (por ejemplo estrabismo concomitante, estrabismo vertical, parálisis rectus lateral, nistagmo, miopatía distiroide), calambre de escritor, blefarospasmo, bruxismo, enfermedad de Wilson, temblor, tics, mioclono segmental, espasmos, espasmos debidos a esclerosis múltiple crónica, espasticidad resultante en control anormal de la vejiga, animus, espasmos de espalda, charley horse, dolores de cabeza por tensión, síndrome pélvico de levator, espina bífida, disquinesia tardía, enfermedad de Parkinson, tartamudeo, espasmo hemifacial, trastorno de los parpados, parálisis cerebral, espasticidad focal, colitis espasmódica, vejiga neurogénica, anismo, miembros espásticos, tics, temblores, bruxismo, fisura anal, achalasia, disfagia, lagrimeo, hiperhidrosis, salivación excesiva, secreciones gastrointestinales excesivas, dolor muscular (por ejemplo, dolor por espasmos musculares), dolor de cabeza (por ejemplo dolor de cabeza por tensión), surcos de cejas, arrugas de la piel, cáncer, trastornos uterinos, trastornos urogenitales, inflamación neurogénico crónico, y un trastorno de los músculos lisos. Reivindicación 23: Una toxina clostridial diseñada sustancialmente como se describe en la presente y con referencia a los dibujos adjuntos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1312317.9A GB201312317D0 (en) | 2013-07-09 | 2013-07-09 | Cationic neurotoxins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR132701A2 true AR132701A2 (es) | 2025-07-23 |
Family
ID=49033565
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140102553A AR096869A1 (es) | 2013-07-09 | 2014-07-10 | Neurotoxinas catiónicas |
| ARP200101165A AR118777A2 (es) | 2013-07-09 | 2020-04-24 | Neurotoxinas catiónicas |
| ARP240101240A AR132701A2 (es) | 2013-07-09 | 2024-05-16 | Neurotoxinas catiónicas |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140102553A AR096869A1 (es) | 2013-07-09 | 2014-07-10 | Neurotoxinas catiónicas |
| ARP200101165A AR118777A2 (es) | 2013-07-09 | 2020-04-24 | Neurotoxinas catiónicas |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US9920310B2 (es) |
| EP (2) | EP3943105A3 (es) |
| JP (4) | JP6850127B2 (es) |
| KR (3) | KR102617830B1 (es) |
| CN (2) | CN112961227A (es) |
| AR (3) | AR096869A1 (es) |
| AU (1) | AU2014288953C1 (es) |
| CA (1) | CA2917009A1 (es) |
| DK (1) | DK3019190T3 (es) |
| EA (2) | EA202191745A1 (es) |
| ES (1) | ES2881301T3 (es) |
| GB (1) | GB201312317D0 (es) |
| HU (1) | HUE055733T2 (es) |
| IL (3) | IL243330B (es) |
| MX (2) | MX385103B (es) |
| PL (1) | PL3019190T3 (es) |
| PT (1) | PT3019190T (es) |
| SA (1) | SA516370371B1 (es) |
| SG (2) | SG11201600150UA (es) |
| TW (3) | TWI694081B (es) |
| UA (1) | UA126889C2 (es) |
| WO (1) | WO2015004461A1 (es) |
| ZA (1) | ZA201801413B (es) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201312317D0 (en) * | 2013-07-09 | 2013-08-21 | Syntaxin Ltd | Cationic neurotoxins |
| AU2015301737B2 (en) * | 2014-08-12 | 2021-01-28 | Biomadison, Inc. | Botulinum neurotoxins with modified light chain specifity and methods for producing same |
| WO2016110662A1 (en) * | 2015-01-09 | 2016-07-14 | Ipsen Bioinnovation Limited | Cationic neurotoxins |
| GB201517450D0 (en) | 2015-10-02 | 2015-11-18 | Ipsen Biopharm Ltd | Method |
| GB201607901D0 (en) * | 2016-05-05 | 2016-06-22 | Ipsen Biopharm Ltd | Chimeric neurotoxins |
| EP3481852B1 (en) * | 2016-07-08 | 2022-12-07 | Children's Medical Center Corporation | A novel botulinum neurotoxin and its derivatives |
| TW201814045A (zh) * | 2016-09-16 | 2018-04-16 | 英商艾普森生物製藥有限公司 | 製造雙鏈梭狀芽孢桿菌神經毒素之方法 |
| TWI810228B (zh) * | 2017-12-20 | 2023-08-01 | 英商艾普森生物製藥有限公司 | 自主神經系統障礙之治療 |
| US11707510B2 (en) * | 2018-02-16 | 2023-07-25 | Preclinics Discovery Gmbh | Nucleic acid-based botulinum neurotoxin for therapeutic use |
| US20220016221A1 (en) | 2018-12-05 | 2022-01-20 | Ipsen Biopharm Limited | Treatment of symptoms of traumatic brain injury |
| GB201914034D0 (en) | 2019-09-30 | 2019-11-13 | Ipsen Biopharm Ltd | Treatment of neurological disorders |
| GB202001353D0 (en) | 2020-01-31 | 2020-03-18 | Ipsen Biopharm Ltd | Treatment of skin conditions |
| GB202003813D0 (en) | 2020-03-16 | 2020-04-29 | Ipsen Biopharm Ltd | Treatment of upper facial lines |
| TWI825396B (zh) * | 2020-03-16 | 2023-12-11 | 英商艾普森生物製藥有限公司 | 肢體痙攣之治療 |
| GB202011055D0 (en) | 2020-07-17 | 2020-09-02 | Ipsen Bioinnovation Ltd | Treatment of post-operative pain |
| WO2022073360A1 (zh) * | 2020-10-10 | 2022-04-14 | 广州东盛生物科技有限公司 | 构建新型冠状病毒疫苗的方法及其应用 |
| GB202100566D0 (en) | 2021-01-15 | 2021-03-03 | Ipsen Biopharm Ltd | Treatment of brain damage |
| GB202103372D0 (en) | 2021-03-11 | 2021-04-28 | Ipsen Biopharm Ltd | Modified clostridial neurotoxins |
| JP2024513191A (ja) | 2021-03-30 | 2024-03-22 | イプセン バイオファーム リミテッド | 疼痛及び炎症性障害の処置 |
| KR20230155007A (ko) | 2021-03-30 | 2023-11-09 | 입센 바이오팜 리미티드 | 통증 ＆ 염증성 장애의 치료를 위한 촉매 불활성 클로스트리디움 신경독소 |
| EP4401759B1 (en) | 2021-09-16 | 2026-02-18 | Ipsen Biopharm Limited | Modified bont/a for use in the treatment of cervical dystonia |
| GB202113602D0 (en) | 2021-09-23 | 2021-11-10 | Ipsen Biopharm Ltd | Treatment of a disorder affecting an eyelid muscle of a subject |
| EP4404955A1 (en) | 2021-09-23 | 2024-07-31 | Ipsen Biopharm Limited | Modified bont/a for use in the treatment of a disorder affecting an eyelid muscle of a subject |
| KR102941554B1 (ko) | 2021-10-22 | 2026-03-19 | 비피메드(주) | 보툴리눔 유래 펩타이드를 포함하는 탈모개선용 조성물 |
| US20240408184A1 (en) * | 2021-10-25 | 2024-12-12 | Bpmed Co., Ltd. | Composition comprising botulinum-derived peptide for pain relief |
| GB202116795D0 (en) | 2021-11-22 | 2022-01-05 | Ipsen Biopharm Ltd | Treatment of visceral pain |
| GB202206353D0 (en) | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of cervical dystonia |
| GB202206348D0 (en) | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of limb spasticity |
| GB202213479D0 (en) | 2022-09-14 | 2022-10-26 | Ipsen Biopharm Ltd | Cell-free clostridial neurotoxin assays |
| CN115819526A (zh) * | 2022-12-02 | 2023-03-21 | 海雅美生物技术(珠海)有限公司 | 一种重组肉毒杆菌神经毒素及其制备方法和应用 |
| CH720447A2 (de) | 2023-01-20 | 2024-07-31 | Abbvie Inc | Zusammensetzungen von clostridium botulinum neurotoxin serotyp a |
| CH720444A2 (de) | 2023-01-20 | 2024-07-31 | Abbvie Inc | Clostridium botulinum serotyp a neurotoxin (bont/a)- sequenzvarianten |
| GB202318884D0 (en) | 2023-12-11 | 2024-01-24 | Ipsen Biopharm Ltd | Formulation |
| GB202320108D0 (en) | 2023-12-28 | 2024-02-14 | Ipsen Biopharm Ltd | Biosensor |
| DE102025101336A1 (de) | 2024-01-19 | 2025-07-24 | Abbvie Inc. | Zusammensetzungen von clostridium botulinum neurotoxin serotyp a und verbesserte trocknungsprozesse |
| GB202404021D0 (en) | 2024-03-20 | 2024-05-01 | Ipsen Biopharm Ltd | Cell-based neurotoxin assay |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993015766A1 (en) | 1992-02-10 | 1993-08-19 | Seragen, Inc. | Desensitization to specific allergens |
| GB9305735D0 (en) | 1993-03-19 | 1993-05-05 | North John R | Novel agent for controlling cell activity |
| DE122009000066I2 (de) | 1993-06-10 | 2010-12-30 | Allergan Inc | Behandlung von neuromuskulären Störungen und Zuständen mit verschiedenen botulinen Serotypen |
| US5437291A (en) | 1993-08-26 | 1995-08-01 | Univ Johns Hopkins | Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction |
| US6974578B1 (en) | 1993-12-28 | 2005-12-13 | Allergan, Inc. | Method for treating secretions and glands using botulinum toxin |
| US20040126396A1 (en) | 1993-12-28 | 2004-07-01 | Allergan, Inc. | Botulinum toxin treatment for strabismus |
| US5670484A (en) | 1994-05-09 | 1997-09-23 | Binder; William J. | Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders |
| US5714469A (en) | 1994-09-01 | 1998-02-03 | Smithkline Beecham Corporation | Method of treating sepsis |
| GB9508204D0 (en) | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
| US7192596B2 (en) | 1996-08-23 | 2007-03-20 | The Health Protection Agency Ipsen Limited | Recombinant toxin fragments |
| GB9617671D0 (en) | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
| US6063768A (en) | 1997-09-04 | 2000-05-16 | First; Eric R. | Application of botulinum toxin to the management of neurogenic inflammatory disorders |
| GB9721189D0 (en) | 1997-10-08 | 1997-12-03 | Speywood Lab The Limited | Analgesic conjugates |
| CN1241945C (zh) | 1998-05-13 | 2006-02-15 | 拜欧特康生化技术开发和咨询有限公司 | 用于抑制肥大细胞脱粒的杂合蛋白质及其用途 |
| DE69910216T2 (de) | 1998-07-22 | 2004-02-19 | Osprey Pharmaceuticals Ltd., Calgary | Konjugate zur behandlung von entzündungskrankheiten und von assozierter gewebeschädigung |
| GB9818548D0 (en) | 1998-08-25 | 1998-10-21 | Microbiological Res Authority | Treatment of mucas hypersecretion |
| US6776990B2 (en) | 1999-04-08 | 2004-08-17 | Allergan, Inc. | Methods and compositions for the treatment of pancreatitis |
| US6358697B2 (en) | 1999-04-21 | 2002-03-19 | Children's Hospital Medical Center | Intracellular pharmaceutical targeting |
| AU783450B2 (en) * | 1999-05-12 | 2005-10-27 | United States Army Medical Research Materiel Command (Usamrmc) | Recombinant vaccine against botulinum neurotoxin |
| US6767544B2 (en) | 2002-04-01 | 2004-07-27 | Allergan, Inc. | Methods for treating cardiovascular diseases with botulinum toxin |
| US6358917B1 (en) | 1999-08-24 | 2002-03-19 | Jean D. A. Carruthers | Cosmetic use of botulinum toxin for treatment of downturned mouth |
| ATE348178T1 (de) | 1999-08-25 | 2007-01-15 | Allergan Inc | Aktivierbare rekombinante neurotoxine |
| GB9922554D0 (en) | 1999-09-23 | 1999-11-24 | Microbiological Res Authority | Inhibition of secretion from non-neuronal cells |
| US6113915A (en) | 1999-10-12 | 2000-09-05 | Allergan Sales, Inc. | Methods for treating pain |
| US6265379B1 (en) | 1999-10-13 | 2001-07-24 | Allergan Sales, Inc. | Method for treating otic disorders |
| US7838008B2 (en) | 1999-12-07 | 2010-11-23 | Allergan, Inc. | Methods for treating diverse cancers |
| US6139845A (en) | 1999-12-07 | 2000-10-31 | Allergan Sales, Inc. | Method for treating cancer with a neurotoxin |
| US6143306A (en) | 2000-01-11 | 2000-11-07 | Allergan Sales, Inc. | Methods for treating pancreatic disorders |
| US6337075B1 (en) | 2000-01-11 | 2002-01-08 | Allergan Sales, Inc. | Methods for treating diabetes |
| US6261572B1 (en) | 2000-01-11 | 2001-07-17 | Allergan Sales, Inc. | Method for treating a pancreatic disorder with a neurotoxin |
| US6641820B1 (en) | 2000-01-19 | 2003-11-04 | Allergan, Inc. | Clostridial toxin derivatives and methods to treat pain |
| US6524580B1 (en) | 2000-02-15 | 2003-02-25 | Allergan Sales, Inc. | Method for treating thyroid disorders |
| US6464986B1 (en) | 2000-04-14 | 2002-10-15 | Allegan Sales, Inc. | Method for treating pain by peripheral administration of a neurotoxin |
| US6299893B1 (en) | 2000-04-17 | 2001-10-09 | Marvin Schwartz | Method to reduce hair loss and stimulate hair regrowth |
| US6565870B1 (en) | 2000-04-28 | 2003-05-20 | Allergan, Inc. | Methods for treating bone tumors |
| US6306403B1 (en) | 2000-06-14 | 2001-10-23 | Allergan Sales, Inc. | Method for treating parkinson's disease with a botulinum toxin |
| US6903187B1 (en) | 2000-07-21 | 2005-06-07 | Allergan, Inc. | Leucine-based motif and clostridial neurotoxins |
| US6423319B1 (en) | 2000-10-04 | 2002-07-23 | Allergan Sales, Inc. | Methods for treating muscle injuries |
| US6827931B1 (en) | 2000-10-20 | 2004-12-07 | Allergan, Inc. | Method for treating endocrine disorders |
| US7273722B2 (en) | 2000-11-29 | 2007-09-25 | Allergan, Inc. | Neurotoxins with enhanced target specificity |
| US20040028613A1 (en) | 2001-06-25 | 2004-02-12 | Nastech Pharmaceutical Company Inc | Dopamine agonist formulations for enhanced central nervous system delivery |
| US6623742B2 (en) | 2001-09-17 | 2003-09-23 | Allergan, Inc. | Methods for treating fibromyalgia |
| US7255866B2 (en) | 2001-09-17 | 2007-08-14 | Allergan, Inc. | Botulinum toxin therapy for fibromyalgia |
| US6921538B2 (en) | 2002-05-10 | 2005-07-26 | Allergan, Inc. | Therapeutic treatments for neuropsychiatric disorders |
| CA2501856A1 (en) | 2002-10-15 | 2004-04-29 | Allergan, Inc. | Botulinum toxin dental therapies and procedures |
| US7238357B2 (en) | 2002-11-05 | 2007-07-03 | Allergan, Inc. | Methods for treating ulcers and gastroesophageal reflux disease |
| US7166575B2 (en) | 2002-12-17 | 2007-01-23 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity |
| US8071550B2 (en) | 2003-03-03 | 2011-12-06 | Allergan, Inc. | Methods for treating uterine disorders |
| US6838434B2 (en) | 2003-05-02 | 2005-01-04 | Allergan, Inc. | Methods for treating sinus headache |
| US7220422B2 (en) | 2003-05-20 | 2007-05-22 | Allergan, Inc. | Methods and compositions for treating eye disorders |
| US20040253274A1 (en) | 2003-06-11 | 2004-12-16 | Allergan, Inc. | Use of a clostridial toxin to reduce appetite |
| DE102004043009A1 (de) | 2004-09-06 | 2006-03-23 | Toxogen Gmbh | Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen |
| AU2005311086B2 (en) | 2004-12-01 | 2012-03-29 | Allergan, Inc. | Fusion proteins |
| ZA200707352B (en) * | 2005-03-03 | 2009-04-29 | Revance Therapeutics Inc | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
| AU2006227816B2 (en) * | 2005-03-15 | 2012-04-05 | Allergan, Inc. | Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems |
| DE102005019302A1 (de) | 2005-04-26 | 2006-11-16 | Toxogen Gmbh | Carrier zum Targeting von Nervenzellen |
| ATE518882T1 (de) | 2005-09-19 | 2011-08-15 | Allergan Inc | Mit clostridientoxin aktivierbare clostridientoxine |
| EP1834962A1 (de) | 2006-03-15 | 2007-09-19 | Biotecon Therapeutics GmbH | PEGyliertes mutiertes Clostridium botulinum Toxin |
| WO2008105901A2 (en) | 2006-07-11 | 2008-09-04 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capability and enhanced targeting activity |
| US8486422B2 (en) * | 2007-07-26 | 2013-07-16 | Allergan, Inc. | Methods of activating clostridial toxins |
| WO2009015840A2 (en) * | 2007-07-27 | 2009-02-05 | Merz Pharma Gmbh & Co. Kgaa | Polypeptide for targeting of neural cells |
| US8445650B2 (en) * | 2007-09-25 | 2013-05-21 | Thomas Jefferson University | Mutant botulinum neurotoxin serotype A polypeptide and uses thereof |
| MX2010004502A (es) * | 2007-10-23 | 2010-06-17 | Allergan Inc | Metodos para tratar trastornos neurologicos urogenitales usando toxinas clostridiales modificadas. |
| HUE037595T2 (hu) * | 2008-12-31 | 2018-09-28 | Revance Therapeutics Inc | Injektálható botulinum toxin készítmények |
| GB0903006D0 (en) | 2009-02-23 | 2009-04-08 | Syntaxin Ltd | Modified non-cytotoxic proteases |
| AU2010236613B2 (en) | 2009-04-14 | 2016-07-07 | Mcw Research Foundation, Inc. | Engineered botulinum neurotoxin |
| JP4900443B2 (ja) | 2009-09-30 | 2012-03-21 | 大日本印刷株式会社 | 色素増感型太陽電池 |
| EP2650003B1 (en) * | 2010-05-20 | 2016-07-27 | Allergan, Inc. | Degradable clostridial toxins |
| US8853360B2 (en) | 2010-06-23 | 2014-10-07 | Wisconsin Alumni Research Foundation | Engineered botulinum neurotoxin C1 with selective substrate specificity |
| US20120189677A1 (en) | 2011-01-20 | 2012-07-26 | Stephen Tonge | Formulations |
| BR112014011137A2 (pt) * | 2011-11-09 | 2018-06-12 | Merz Pharma Gmbh & Co Kgaa | polinucleotídeo, vetor, célula hospedeira, polipeptídeo, anticorpo, método para a produção de um polipeptídeo, método para a produção de um medicamento |
| UA116985C2 (uk) * | 2012-05-30 | 2018-06-11 | Президент Енд Феллоуз Оф Гарвард Колледж | Рекомбінантний ботулінічний нейротоксин |
| GB201312317D0 (en) * | 2013-07-09 | 2013-08-21 | Syntaxin Ltd | Cationic neurotoxins |
| GB201407525D0 (en) * | 2014-04-29 | 2014-06-11 | Syntaxin Ltd | Manufacture of recombinant clostridium botulinum neurotoxins |
-
2013
- 2013-07-09 GB GBGB1312317.9A patent/GB201312317D0/en not_active Ceased
-
2014
- 2014-07-09 US US14/903,458 patent/US9920310B2/en active Active
- 2014-07-09 KR KR1020217040836A patent/KR102617830B1/ko active Active
- 2014-07-09 EA EA202191745A patent/EA202191745A1/ru unknown
- 2014-07-09 MX MX2016000047A patent/MX385103B/es unknown
- 2014-07-09 TW TW103123643A patent/TWI694081B/zh active
- 2014-07-09 TW TW111118323A patent/TWI813291B/zh active
- 2014-07-09 EA EA201690189A patent/EA039105B1/ru unknown
- 2014-07-09 CA CA2917009A patent/CA2917009A1/en active Pending
- 2014-07-09 PT PT147476972T patent/PT3019190T/pt unknown
- 2014-07-09 EP EP21167912.1A patent/EP3943105A3/en active Pending
- 2014-07-09 EP EP14747697.2A patent/EP3019190B1/en active Active
- 2014-07-09 AU AU2014288953A patent/AU2014288953C1/en active Active
- 2014-07-09 KR KR1020237044106A patent/KR20240005140A/ko not_active Ceased
- 2014-07-09 CN CN202110239457.8A patent/CN112961227A/zh active Pending
- 2014-07-09 TW TW109114599A patent/TWI776147B/zh active
- 2014-07-09 HU HUE14747697A patent/HUE055733T2/hu unknown
- 2014-07-09 SG SG11201600150UA patent/SG11201600150UA/en unknown
- 2014-07-09 KR KR1020167003051A patent/KR102340476B1/ko active Active
- 2014-07-09 SG SG10202005416PA patent/SG10202005416PA/en unknown
- 2014-07-09 DK DK14747697.2T patent/DK3019190T3/da active
- 2014-07-09 PL PL14747697T patent/PL3019190T3/pl unknown
- 2014-07-09 CN CN201480043806.7A patent/CN105492020B/zh active Active
- 2014-07-09 JP JP2016524894A patent/JP6850127B2/ja active Active
- 2014-07-09 WO PCT/GB2014/052097 patent/WO2015004461A1/en not_active Ceased
- 2014-07-09 UA UAA201601094A patent/UA126889C2/uk unknown
- 2014-07-09 ES ES14747697T patent/ES2881301T3/es active Active
- 2014-07-10 AR ARP140102553A patent/AR096869A1/es active IP Right Grant
-
2015
- 2015-12-24 IL IL243330A patent/IL243330B/en active IP Right Grant
-
2016
- 2016-01-07 MX MX2021006714A patent/MX2021006714A/es unknown
- 2016-01-07 SA SA516370371A patent/SA516370371B1/ar unknown
-
2018
- 2018-02-06 US US15/889,317 patent/US11034947B2/en active Active
- 2018-03-01 ZA ZA2018/01413A patent/ZA201801413B/en unknown
-
2019
- 2019-04-01 JP JP2019069960A patent/JP7360802B2/ja active Active
- 2019-11-19 IL IL270769A patent/IL270769B/en active IP Right Grant
-
2020
- 2020-04-24 AR ARP200101165A patent/AR118777A2/es unknown
- 2020-08-25 IL IL276915A patent/IL276915B/en unknown
-
2021
- 2021-12-21 JP JP2021206753A patent/JP7434263B2/ja active Active
-
2024
- 2024-02-07 JP JP2024016868A patent/JP2024054234A/ja active Pending
- 2024-05-16 AR ARP240101240A patent/AR132701A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR132701A2 (es) | Neurotoxinas catiónicas | |
| AR108689A1 (es) | Neurotoxinas clostridiales quiméricas | |
| JP2022046597A5 (es) | ||
| JP2019528042A5 (es) | ||
| Truong et al. | Botulinum toxin: clinical use | |
| JP2024012421A5 (es) | ||
| SA520411802B1 (ar) | Snare سموم عصبية من البُتيولين تشطر غير العصبي | |
| JP2016513082A5 (es) | ||
| EP4599847A3 (en) | Prefusion coronavirus spike proteins and their use | |
| JP2024512397A5 (es) | ||
| PH12020550529A1 (en) | Recombinant bacterium capable of producing l-lysine, construction method thereof and production method of l-lysine | |
| WO2019067815A3 (en) | A neurotoxin-like toxin and uses thereof | |
| WO2019040935A8 (en) | Evolution of bont peptidases | |
| RU2015124069A (ru) | Способы производства протеолитически процессированных полипептидов | |
| NZ749810A (en) | A novel botulinum neurotoxin and its derivatives | |
| SA520412669B1 (ar) | تصنيع ذيفانات عصبية ناتجة عن معاودة الارتباط الجيني من المطثية الوشيقية | |
| EP3791892A3 (en) | Smart car devices and de car polypeptides for treating disease and methods of enhancing immune responses | |
| BR112012008028A2 (pt) | sistema para estimulação do nervo trigêmeo para tratamento de um distúrbio neuropsquiátrico, unidade de eletrodo cutâneo, método para tratar um distúrbio neuropsquiátrico, e, kit para estimulação do nervo trigêmeo para tratamento de um distúrbio neuropsiquiátrico | |
| Evidente et al. | An update on the neurologic applications of botulinum toxins | |
| US20190161783A1 (en) | Production of activated clostridial neurotoxins | |
| IL273435B2 (en) | Botulinum neurotoxin A subtype 6 and methods of pharmacological use | |
| JP2023090955A5 (es) | ||
| TH2101001791A (th) | คลอสทริเดียลนิวโรทอกซินซึ่งประกอบรวมด้วยลูปการกระตุ้นแบบเอ็กโซจีเนียส | |
| RU2023125554A (ru) | Клостридиальные нейротоксины, содержащие экзогенную петлю активации | |
| RU2025110789A (ru) | Клостридиальные нейротоксины, содержащие активирующий сайт расщепления эндосомальной протеазой |